Ferring Pharmaceuticals, Inc.
A Study With Pentasa in Patients With Active Crohn's Disease
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00862121
- Locations
- 🇺🇸
Clinical Research of West Florida, Clearwater, Florida, United States
🇺🇸Center for Digestive and Liver Disease, Inc, Mexico, Montana, United States
🇩🇪Gemeinschaftspraxis, Leipzig, Germany
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT00833248
- Locations
- 🇬🇧
Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom
🇫🇷Clinique du Parc, Toulouse, France
🇫🇷Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT00831233
- Locations
- 🇪🇸
Fundación Puigvert, Barcelona, Spain
🇪🇸Fundacion Hospital Alcorcón, Alcorcon, Spain
🇪🇸Hospital de Basurto, Bilbao (Bizkaia), Spain
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
- Conditions
- Cervical RipeningInduction of Labor
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 374
- Registration Number
- NCT00828711
- Locations
- 🇺🇸
University of Texas Health Sciences Center at Houston, Houston, Texas, United States
🇺🇸Precision Trials, Phoenix, Arizona, United States
🇺🇸Tuscon Medical Center, Tucson, Arizona, United States
Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00819156
- Locations
- 🇧🇪
UZ Gasthuisberg, Leuven, Belgium
🇩🇪Urologische Universitätsklinikum, Mannheim, Germany
🇭🇺Pez Aladar County Hospital, Györ, Hungary
Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT00818623
- Locations
- 🇩🇰
KAS Herlev, Herlev, Denmark
🇸🇪Sahlgrenska Universitetssjukehuset, Göteborg, Sweden
🇫🇮TAYS, Tampere, Finland
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT00819247
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Stirling Royal Infirmary, Stirling, United Kingdom
🇬🇧Bristol Royal Infirmary, Bristol, United Kingdom
Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
- Conditions
- Polycystic Ovarian SyndromeInfertility
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-01-27
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT00805935
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Women & Infants' Hospital of RI, Providence, Rhode Island, United States
🇺🇸Conceptions Reproductive Associates of Colorado, Littleton, Colorado, United States
MENOPUR® Versus FOLLISTIM®
- Conditions
- Infertility
- Interventions
- Drug: Progestrone vaginal insert
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 173
- Registration Number
- NCT00802360
- Locations
- 🇺🇸
A Woman's Center for Reproductive Medicine, Baton Rouge, Louisiana, United States
🇺🇸Huntington Reproductive Center, Pasadena, California, United States
🇺🇸Women's Medical Research Group, LLC, Clearwater, Florida, United States
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT00801242
- Locations
- 🇫🇷
Clinique Beausoleil, Montpellier, France
🇫🇷CHU Hôtel-Dieu, NANTES cedex 1, France
🇫🇷Hôpital Tenon, PARIS cedex 20, France